GSK loses British court ruling on combination patent for Advair

A British court has ruled that GlaxoSmithKline's combination patent for its Seretide asthma drug -- known as Advair in the U.S. -- is not valid because it did not include enough new components to qualify. The court's ruling, which GSK said it might appeal, opens the door for four manufacturers of generic drugs to make their own versions of the drug.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Director of Operations - GBS
Mayo Clinic
Rochester, MN
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior Vice President, Clinical Affairs & Strategic Partnerships
America's Health Insurance Plans (AHIP)
Washington, DC